Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ovarian cancer gene hunt: 300 patients to shape future therapies

NCT ID NCT06127446

Knowledge-focused Sponsor: National Health Research Institutes, Taiwan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to collect and analyze genetic information from 300 Taiwanese women with ovarian cancer. Researchers will look at tumor samples and medical records to find gene changes linked to treatment response and survival. The goal is to build a database that helps develop personalized treatments and improve outcomes for ovarian cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Stage I to IV high grade serous or clear cell ovarian cancer

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 and above. 2. Stage I to IV high grade serous or clear cell carcinoma of ovary, peritoneal and fallopian tube. 3. Patients with primary ovarian cancer had undergone primary surgery. Patients with recurrent ovarian cancer had undergone primary surgery (and biopsy/surgery for recurrent tumors). 4. Tumor tissues before neoadjuvant therapy will be collected for patients receiving surgery after any neoadjuvant treatment. 5. Willingness to provide the surgical tissues of primary tumors, non-tumor part normal tissue (and paired recurrent tumors in 80 patients). 6. Willingness to provide blood sample of 20ml within four weeks after registration (in at least 72 patients of primary ovarian cancer and 72 patients of recurrent ovarian cancer). 7. Patient fully understand the protocol with the willingness to have regular follow-up. 8. Life expectancy more than 3 months. Exclusion Criteria: 1. Concomitant ovarian and endometrial cancer 2. Paraffin tissue tumor block older than five years. 3. Tumor specimen of primary surgery or recurrent biopsy/surgery are not qualified for genetic testing. 4. Concomitant malignancy under surveillance or treatment in the past three years (excluding curatively treated basal or squamous cell skin carcinoma or carcinoma in situ) 5. Inability to cooperate or undesirable compliance to the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clear cell ovarian carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian clear cell cancer ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cathay General Hospital

    RECRUITING

    Taipei, Taiwan

  • Chang Gung Medical Foundation

    RECRUITING

    Kaohsiung City, Taiwan

  • China Medical University Hospital

    RECRUITING

    Taichung, Taiwan

  • Kaohsiung Veterans General Hospital

    RECRUITING

    Kaohsiung City, Taiwan

  • Mackay Memorial Hospital

    RECRUITING

    Taipei, Taiwan

  • National Cheng Kung University Hospital

    RECRUITING

    Tainan, Taiwan

  • National Taiwan University Hospital

    RECRUITING

    Taipei, Taiwan

  • Taichung Veterans General Hospital

    RECRUITING

    Taichung, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.